Patrick Wareing
LightNews LightNews
patrickwareing.bsky.social
Patrick Wareing
@patrickwareing.bsky.social
87 followers 490 following 310 posts
Weekly news to your inbox every Monday morning 👉https://patrickwareing.kit.com/a70ed18837
Posts Replies Media Videos
Pinned
patrickwareing.bsky.social
Patrick Wareing @patrickwareing.bsky.social · Jul 24
Too much news? Not enough time?

Stay up to date with the latest B2B life science news

patrickwareing.kit.com/email-signup
Life Science News to Your Inbox
Get a weekly summary of the past week's life science, pharma and biotech news
patrickwareing.kit.com
patrickwareing.bsky.social
Mayne Pharma Rejects Cosette’s Attempt to Terminate Scheme Deal

patrickwareing.com/news/mayne-p...
Mayne Pharma Rejects Cosette’s Attempt to Terminate Scheme Deal - Patrick Wareing
Mayne Pharma has rejected Cosette Pharmaceuticals’ attempt to terminate their scheme implementation deed (SID), asserting that the termination notice is
patrickwareing.com
December 12, 2025 at 4:45 PM
patrickwareing.bsky.social
Formation Bio Makes $605M Play for Lynk’s TYK2 Inhibitor

patrickwareing.com/news/formati...
Formation Bio Makes $605M Play for Lynk’s TYK2 Inhibitor - Patrick Wareing
Formation Bio has entered a landmark agreement with Lynk Pharmaceuticals to acquire worldwide rights (excluding Greater China) to LNK01006, a next-generation,
patrickwareing.com
December 12, 2025 at 2:30 PM
patrickwareing.bsky.social
Teva Moves to Delist 200+ Patents from FDA Orange Book After FTC Challenge

patrickwareing.com/news/teva-mo...
Teva Moves to Delist 200+ Patents from FDA Orange Book After FTC Challenge - Patrick Wareing
Teva Pharmaceuticals has agreed to delist more than 200 patents from the FDA’s Orange Book, a move the Federal Trade Commission (FTC) is calling a major win
patrickwareing.com
December 12, 2025 at 10:45 AM
patrickwareing.bsky.social
FDA Finalizes Guidance on Biosimilar Promotional Materials, Clarifying Regulatory Expectations

patrickwareing.com/news/fda-fin...
FDA Finalizes Guidance on Biosimilar Promotional Materials, Clarifying Regulatory Expectations - Patrick Wareing
The U.S. Food and Drug Administration (FDA) has released final guidance detailing the requirements for promotional labeling and advertising of biosimilars,
patrickwareing.com
December 11, 2025 at 5:01 PM
patrickwareing.bsky.social
Scientists Prepare for Clinical Trials of AI-Designed Antibodies, Ushering in a New Era of Drug Discovery

patrickwareing.com/news/scienti...
Scientists Prepare for Clinical Trials of AI-Designed Antibodies, Ushering in a New Era of Drug Discovery - Patrick Wareing
Scientists are preparing to launch clinical trials for antibodies that were designed from scratch by artificial intelligence, marking a significant turning
patrickwareing.com
December 11, 2025 at 3:15 PM
patrickwareing.bsky.social
Abivax Shares Surge Over 20% Amid Rumors of Eli Lilly Acquisition Bid

patrickwareing.com/news/abivax-...
Abivax Shares Surge Over 20% Amid Rumors of Eli Lilly Acquisition Bid - Patrick Wareing
French biotechnology company Abivax experienced a dramatic rise in its stock price on December 10, 2025, with shares jumping over 20% amid rumors that Eli
patrickwareing.com
December 11, 2025 at 10:15 AM
patrickwareing.bsky.social
Pfizer Signs $1.9B Pact for Fosun Unit’s GLP-1 Drug YP05002

patrickwareing.com/news/pfizer-...
Pfizer Signs $1.9B Pact for Fosun Unit’s GLP-1 Drug YP05002 - Patrick Wareing
Pfizer has announced a significant expansion of its obesity drug portfolio with a $1.9 billion licensing deal for Yao Pharma’s oral GLP-1 receptor agonist
patrickwareing.com
December 10, 2025 at 5:15 PM
patrickwareing.bsky.social
GSK Starts Unwinding Ideaya Alliance, Returning Two Synthetic Lethality Programs

patrickwareing.com/news/gsk-sta...
GSK Starts Unwinding Ideaya Alliance, Returning Two Synthetic Lethality Programs - Patrick Wareing
GSK has moved to discontinue its long‑running synthetic lethality collaboration with Ideaya Biosciences, formally giving notice that it will terminate the
patrickwareing.com
December 10, 2025 at 3:00 PM
patrickwareing.bsky.social
Dr. Reddy’s Signs $370M Licensing Deal for Immutep’s LAG‑3 Immunotherapy Eftilagimod Alfa

patrickwareing.com/news/dr-redd...
Dr. Reddy’s Signs $370M Licensing Deal for Immutep’s LAG‑3 Immunotherapy Eftilagimod Alfa - Patrick Wareing
Dr. Reddy’s Laboratories has signed a major oncology licensing deal for eftilagimod alfa (efti), Immutep’s lead LAG‑3–based immunotherapy, in an agreement
patrickwareing.com
December 10, 2025 at 1:33 PM
patrickwareing.bsky.social
SeaBeLife Enters Joint Development Agreement with Unither Pharmaceuticals for Topical Ophthalmic SBL03

patrickwareing.com/news/seabeli...
SeaBeLife Enters Joint Development Agreement with Unither Pharmaceuticals for Topical Ophthalmic SBL03 - Patrick Wareing
SeaBeLife, a French biotech focused on cellular necrosis, has announced a joint development agreement with Unither Pharmaceuticals to advance its lead drug
patrickwareing.com
December 9, 2025 at 5:15 PM
patrickwareing.bsky.social
Wave and Structure Therapeutics Stocks Double After Obesity Drug Data Readouts

patrickwareing.com/news/wave-an...
Wave and Structure Therapeutics Stocks Double After Obesity Drug Data Readouts - Patrick Wareing
Wave Life Sciences and Structure Therapeutics both experienced dramatic stock surges after releasing new clinical data for their respective obesity drug
patrickwareing.com
December 9, 2025 at 2:30 PM
patrickwareing.bsky.social
Mirum Gains Hepatitis D Drug in $620M Buyout of Startup Bluejay

patrickwareing.com/news/mirum-g...
Mirum Gains Hepatitis D Drug in $620M Buyout of Startup Bluejay - Patrick Wareing
Mirum Pharmaceuticals has struck a deal to buy Bluejay Therapeutics, a private biotech focused on viral and liver diseases, in a transaction valued at $620
patrickwareing.com
December 9, 2025 at 11:15 AM
patrickwareing.bsky.social
Innovent Biologics Announces Closing of Global Strategic Partnership with Takeda

patrickwareing.com/news/innoven...
Innovent Biologics Announces Closing of Global Strategic Partnership with Takeda - Patrick Wareing
Innovent Biologics has confirmed that its global strategic partnership with Takeda has closed and become effective, following satisfaction of all closing
patrickwareing.com
December 8, 2025 at 5:15 PM
patrickwareing.bsky.social
AstraZeneca’s Latest Amyloidosis Pact with Neurimmune Could Reach $780M

patrickwareing.com/news/astraze...
AstraZeneca’s Latest Amyloidosis Pact with Neurimmune Could Reach $780M - Patrick Wareing
AstraZeneca has returned to Neurimmune for a second amyloidosis asset, signing a licensing pact for the preclinical monoclonal antibody NI009 in light chain
patrickwareing.com
December 8, 2025 at 2:45 PM
patrickwareing.bsky.social
Paradigm Raises $78M to Transform Clinical Research, Acquires Flatiron’s Oncology Trial Unit

patrickwareing.com/news/paradig...
Paradigm Raises $78M to Transform Clinical Research, Acquires Flatiron’s Oncology Trial Unit - Patrick Wareing
Paradigm Health has raised $78 million in a Series B round to scale its technology-first approach to clinical research and redefine how trials are run. The
patrickwareing.com
December 8, 2025 at 10:45 AM
patrickwareing.bsky.social
Pharvaris Reports Positive Phase 3 Results for Oral Hereditary Angioedema Treatment

patrickwareing.com/news/pharvar...
Pharvaris Reports Positive Phase 3 Results for Oral Hereditary Angioedema Treatment - Patrick Wareing
Pharvaris, the Netherlands-based biotech, has delivered promising topline results from its RAPIDe-3 Phase 3 trial evaluating deucrictibant as an oral
patrickwareing.com
December 5, 2025 at 4:45 PM
patrickwareing.bsky.social
Medtronic’s Hugo Surgical Robot Secures US Clearance

patrickwareing.com/news/medtron...
Medtronic’s Hugo Surgical Robot Secures US Clearance - Patrick Wareing
Medtronic has announced that its Hugo Robotic-Assisted Surgery (RAS) System has received FDA clearance for use in the United States, enabling the company to
patrickwareing.com
December 5, 2025 at 2:45 PM
patrickwareing.bsky.social
Triana Secures $120M Series B to Advance Novel Glue Degrader into Clinical Trials

patrickwareing.com/news/triana-...
Triana Secures $120M Series B to Advance Novel Glue Degrader into Clinical Trials - Patrick Wareing
Triana Biomedicines has successfully closed a $120 million Series B financing to propel its pioneering glue degrader platform into the clinic. The round is
patrickwareing.com
December 5, 2025 at 11:45 AM
patrickwareing.bsky.social
Avetra Launches as Next-Generation CRO Focused on Transparency and Faster Study Starts

patrickwareing.com/news/avetra-...
Avetra Launches as Next-Generation CRO Focused on Transparency and Faster Study Starts - Patrick Wareing
Avetra has emerged as a new “next-generation” CRO with a mission to overhaul how clinical trials are run by centering its model around investigative sites
patrickwareing.com
December 4, 2025 at 4:15 PM
patrickwareing.bsky.social
Lantern Pharma Advances AI-Designed Cancer Drug LP-184 After Successful Phase 1a Trial

patrickwareing.com/news/lantern...
Lantern Pharma Advances AI-Designed Cancer Drug LP-184 After Successful Phase 1a Trial - Patrick Wareing
Lantern Pharma, an AI-driven oncology company, is advancing its investigational cancer drug LP-184 after reporting a successful Phase 1a trial in patients
patrickwareing.com
December 4, 2025 at 2:15 PM
patrickwareing.bsky.social
Excelsior Sciences Raises $95M to Reinvent Small Molecule Discovery and Manufacturing

patrickwareing.com/news/excelsi...
Excelsior Sciences Raises $95M to Reinvent Small Molecule Discovery and Manufacturing - Patrick Wareing
Excelsior Sciences has emerged from stealth with $95 million in fresh capital to re-engineer how small-molecule drugs are invented and manufactured. The
patrickwareing.com
December 4, 2025 at 10:30 AM
patrickwareing.bsky.social
Axoltis Pharma Raises €18M to Advance ALS Candidate NX210c

patrickwareing.com/news/axoltis...
Axoltis Pharma Raises €18M to Advance ALS Candidate NX210c - Patrick Wareing
Axoltis Pharma, a French biotech focused on neurodegenerative and neurotraumatic diseases, has raised €18 million in a Series A financing to speed up
patrickwareing.com
December 3, 2025 at 5:30 PM
patrickwareing.bsky.social
Roche’s 15-Minute Whooping Cough Test Cleared in US and Europe Amid Surge in Cases

patrickwareing.com/news/roches-...
Roche’s 15-Minute Whooping Cough Test Cleared in US and Europe Amid Surge in Cases - Patrick Wareing
Roche has secured regulatory green lights on both sides of the Atlantic for its first point-of-care test for whooping cough, as health systems grapple with a
patrickwareing.com
December 3, 2025 at 2:45 PM
patrickwareing.bsky.social
Akebia Promises $12M Upfront for Q32’s Rare Kidney Disease Candidate ADX‑097

patrickwareing.com/news/akebia-...
Akebia Promises $12M Upfront for Q32’s Rare Kidney Disease Candidate ADX‑097 - Patrick Wareing
Akebia Therapeutics has struck a deal to acquire rights to Q32 Bio’s rare kidney disease candidate ADX‑097, committing $12 million in upfront payments as it
patrickwareing.com
December 3, 2025 at 1:23 PM
patrickwareing.bsky.social
Regeneron Makes $150M Bet on Tessera’s Gene Writing Therapy for Rare Lung and Liver Disease

patrickwareing.com/news/regener...
Regeneron Makes $150M Bet on Tessera’s Gene Writing Therapy for Rare Lung and Liver Disease - Patrick Wareing
Regeneron Pharmaceuticals has entered a global collaboration with Tessera Therapeutics to develop and commercialize TSRA-196, an investigational in vivo gene
patrickwareing.com
December 2, 2025 at 5:30 PM